FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer By Ogkologos - June 17, 2026 140 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki Source RELATED ARTICLESMORE FROM AUTHOR Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab No OS Benefit from Continuous as Compared with Fixed-Duration Maintenance Therapy with Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma MOST POPULAR Precision drug slows progression of advanced breast cancer September 21, 2021 EMA Recommends Extension of Indications for Ponatinib Associated with a New... August 7, 2026 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 Cancer Rehabilitation Starts at Diagnosis July 6, 2021 Load more HOT NEWS Cross-Border Network of European Specialists Provides New Treatment Options For Women... 2020 round-up: Our biggest cancer stories of the year Breast Cancer Centers Rarely Follow National Screening Recommendations, Study Says Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October
